Đang chuẩn bị liên kết để tải về tài liệu:
Rationale and design of ON-TRK: A novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors. Larotrectinib is a first-in-class, highly selective, central nervous system-active TRK inhibitor approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and over 40 countries for the treatment of TRK fusion solid tumors in adult and pediatric patients. |

TÀI LIỆU LIÊN QUAN

Moet’s three pilot English language communicational curricula for schools in Vietnam: Rationale, design and implementation

Ebook Dynamic reconstruction of the spine: Part 1

The Nordic long-term OCD treatment study (NordLOTS): Rationale, design, and methods

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Báo cáo y học: "Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods"

Báo cáo y học: The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods

Báo cáo y học: "The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods"

báo cáo khoa học:"The WRITTEN-HEART study (expressive writing for heart healing): rationale and design of a randomized controlled clinical trial of expressive writing in coronary patients referred to residential cardiac rehabilitation"

Báo cáo y học: "Rationale, design and methodology for Intraventricular Pressure Gradients Study: a novel approach f"

Báo cáo y học: "Rationale and design of a proof-of-concept trial investigating the effect of uninterrupted perioperative (par)enteral nutrition on amino acid profile, cardiomyocytes structure, and cardiac perfusion and metabolism of patients undergoing coronary artery bypass grafting"